In addition, the hepatic steatosis percentage and the levels of serum TG, TG, and TC in liver tissues in the EGCG-treated groups were significantly lower than those in the HFD-Fer-1 group (Figures 1C, G, I). This evidence concerns the gene FER and fatty liver disease.